Key result
Exceeding the 2021 KDIGO blood pressure target is not linked to higher mortality in CKD.
Why the study?
The 2021 KDIGO guidelines set a target SBP of 120 mmHg for CKD patients, prompting a comparison of mortality outcomes following the 2021 versus the 2012 guidelines.
Does blood pressure above the 2021 KDIGO target only increase all-cause or cardiovascular mortality compared to blood pressure controlled within both targets in patients with chronic kidney disease?
Observational (n=7,229)
Does blood pressure above the 2021 KDIGO target only increase all-cause or cardiovascular mortality compared to blood pressure controlled within both targets in patients with chronic kidney disease?
Answers are grounded in this paper and cite their sources.
The 2021 KDIGO guidelines' stricter blood pressure target of <120 mmHg did not identify a higher-risk CKD population for mortality compared to the 2012 targets, challenging the mortality benefit of the updated intensive BP goals.
The 2021 Kidney Disease: Improving Global Prognosis (KDIGO) guidelines set a target systolic blood pressure (SBP) of 120 mmHg for chronic kidney disease (CKD) patients. This paper aims to compare mortality outcomes in CKD patients following the 2021 KDIGO guidelines versus the 2012 KDIGO guidelines. We used the National Health and Nutrition Examination Survey (NHANES) database to categorize CKD patients into four groups: "above 2021 KDIGO only", "above 2012 KDIGO only", "above both targets" and "controlled with both targets". We compared differences in all-cause and cardiovascular deaths among these groups. In total, 10,612 CKD patients from the 2001-2018 NHANES database were identified. Subsequently, 2,226 patients lacking mortality information and 1,157 without crucial laboratory data were excluded. 7,229 CKD patients were enrolled, with 50.67% above both targets, 27.1% controlled within both targets, 1.01% above the 2012 KDIGO target, and 21.22% only above the 2021 KDIGO target. In multivariate analyses, the risk of all-cause mortality was not statistically significant (hazard ratio (HR): 0.91, 95% confidence interval (CI): 0.8-1.02, P = 0.11) for patients above the 2021 KDIGO target only compared to those controlled with both targets. Similar results were found for cardiovascular deaths. The 2021 KDIGO guidelines did not differentiate high-risk CKD populations in terms of all-cause death and cardiovascular death, compared with the 2012 KDIGO guidelines.
No takes yet. Share an insight, caveat, or question.
Zou et al. (2025) conducted an observational in Chronic kidney disease (n=7,229). Blood pressure above 2021 KDIGO target only vs. Blood pressure controlled within both targets was evaluated on All-cause mortality (HR 0.91, 95% CI 0.8-1.02, p=0.11). Blood pressure above the 2021 KDIGO target only did not affect all-cause mortality compared to being controlled within both targets in patients with chronic kidney disease.
Synapse has enriched 10 related papers. Consider them for comparative context: